Please assess the completion status of the following clinical trial:

Trial Title: Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female inpatient or outpatients, ages 18-65~Exclusion Criteria:~* Participation in a clinical trial of another drug including olanzapine or aripiprazole within 30 days prior to study entry (visit 1).~* Treatment with clozapine within the past 12 months.~* Have known uncorrected narrow-angle glaucoma.~* Have a diagnosis of Parkinson's disease, dementia or related disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).